Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
|Articles|October 18, 2011
AAP 2011: Speaking with Dr. Natasha Gerbert [Video]
Author(s)Sean Johnson
One of the great thing about covering a medical conference is being able to interact with physicians and thought leaders about the hot topics in their specialty. In this video, Natasha Bergert, MD, a pediatrician from Kansas City, MO, discusses her experience at this year's AAP conference.
Advertisement
One of the great thing about covering a conference is being able to interact with physicians and thought leaders about the hot topics in their specialty. In this video, Natasha Bergert, MD, a pediatrician from Kansas City, MO, discusses her experience at the 2011 American Academy of Pediatrics in Boston.
Read more about what Dr. Begert has to say by visiting her blog,
Advertisement
Related to this article
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
3
I CAN: Ravulizumab Cuts Proteinuria 43% vs Placebo in IgA Nephropathy
4
IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy
5